Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EURopean Trial In Atrial Fibrillation or Flutter Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS)

Next Previous
Trial Profile

EURopean Trial In Atrial Fibrillation or Flutter Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dronedarone (Primary)
  • Indications Atrial fibrillation; Atrial flutter
  • Focus Registrational; Therapeutic Use
  • Acronyms EURIDIS
  • Sponsors Sanofi

    • Most Recent Events

    • 01 Jul 2022 Results of sub-analysis of the ATHENA and EURIDIS/ADONIS studies published in the Journal of Diabetes and its Complications
    • 15 Jan 2022 Results (n=1795) of post hoc analysis of pooled data from two (EURIDIS and ADONIS) assessing the patient characteristics as predictors of dronedarone trough concentrations and characterized the relationship of the trough concentrations of dronedarone with its efficacy and safety, published in the Clinical Cardiology.
    • 12 Jan 2022 Results (n=1229) of post hoc, pooled analysis from NCT00259428 and NCT00259376 assessing safety and efficacy of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function, published in the Clinical Cardiology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top